|
市場調査レポート
商品コード
1184188
整形外科用成長因子の世界市場:規模、シェア、COVID-19の影響分析(2023年~2029年):MedCoreOrthopedic Growth Factor Market Size, Share, and COVID-19 Impact Analysis | Global | 2023-2029 | MedCore |
||||||
整形外科用成長因子の世界市場:規模、シェア、COVID-19の影響分析(2023年~2029年):MedCore |
出版日: 2022年12月30日
発行: iData Research Inc.
ページ情報: 英文 31 Pages
納期: 即日から翌営業日
|
世界の整形外科用成長因子の市場規模は、2022年に8億6,000万米ドルとなりました。同市場は、予測期間中に3.5%のCAGRで拡大し、11億米ドルに達すると予測されています。
当レポートでは、世界の整形外科用成長因子市場について調査し、市場の概要とともに、セグメント別、地域別動向、競合情勢などを提供しています。
In 2022, the global orthopedic growth factor market was valued at $860 million. This is anticipated to increase over the forecast period at a CAGR of 3.5% to reach $1.1 billion.
The orthopedic growth factor market experienced a decline in sales as a result of the Global COVID-19 pandemic. The primary reason for this decrease was the mass cancellation and postponement of scheduled procedures. Although these changes are only temporary, and the market is expected to return to steady growth in the long run, the impact has been significant, and many companies have been forced to accept unprecedented losses in this area for 2020.
Aside from the decline and recovery during 2020 and 2022, associated with the delay and cancellation of elective procedures, the total number of orthopedic growth factor procedures is projected to grow at a mid-single-digit rate over the forecast period.
The global orthopedic growth factor market has been steadily increasing in value over the past few years. Medtronic has been the main leader in the market with its INFUSE® product. However, Wright Medical has been gaining traction with its AUGMENT® product line, which has seen strong growth since its inception in 2015 and the introduction of AUGMENT® Injectable into the market in 2018.
The global orthopedic growth factor market is lead by three main companies: Medtronic, Stryker, and Cerapedics. In 2022, Medtronic was the leader in the orthopedic growth factor market. Medtronic's INFUSE® product remains the gold standard for spinal fusion therapies.